Organ and Tissue Transplantation and Alternatives

• Provides full coverage of product segments including solid organs, experimental xenografts and artificial organs, tissue transplants, and cell transplants
• Details forecasts by product type and application through 2010, including supporting analyses for projections
• Overviews international markets
• Discusses the industry' s structure and the regulatory environment
• Profiles leading companies involved, including placement within the market and strategic analyses of available and emerging products.

This report offers forecasts by product segment from 2008 through 2013, including supporting analyses for projections. Product segments covered consist of solid organs (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation market (e.g., bone, skin, cornea, heart valves), along with the pharmaceuticals that accompany each market. Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.

The arrangement of this report offers an overview of the organ and tissue transplantation market accompanied by analyses and forecasts for each product type and application.

International markets are discussed, and information is provided on industry structure and the regulatory environment. Profiles of leading companies involved with tissue transplantation provide information on placement within the market and strategic analyses of the companies' available and emerging products.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, with the exception of peripheral and umbilical cord blood as a source of stem cells.

Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, transplant surgeons, and pertinent societies' and associations' representatives. Additional data was derived from companies' annual reports and 10Ks, journal articles, prospectus assessments, and government resources.

Information for this report was obtained from industry analysts; the Center for Medicare and Medicaid Services (CMS), the National Institutes of Health (NIH), the Centers for Disease Control (CDC) and other government agencies; the United Network for Organ Sharing; the Organ Procurement and Transplantation Network; the Scientific Registry of Transplant Recipients; literature searches; companies' annual reports and 10Ks; and product literature.